

Original article

Factors Associated With Uncontrolled Hypertension in Patients With and Without Cardiovascular Disease

Alberto Cordero,^{a,*} Vicente Bertomeu-Martínez,^a Pilar Mazón,^b Lorenzo Fácila,^c
Vicente Bertomeu-González,^a Juan Cosín,^d Enrique Galve,^e Julio Núñez,^f
Iñaki Lekuona,^g and José R. González-Juanatey^b

^aDepartamento de Cardiología, Hospital Universitario de San Juan, Sant Joan d'Alacant, Alicante, Spain

^bDepartamento de Cardiología, Hospital Complejo Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain

^cDepartamento de Cardiología, Hospital Provincial de Castellón, Castellón de La Plana, Spain

^dDepartamento de Cardiología, Hospital Arnau de Vilanova, Lleida, Spain

^eDepartamento de Cardiología, Hospital Vall d'Hebron, Barcelona, Spain

^fDepartamento de Cardiología, Hospital Clínico Universitario de Valencia, Valencia, Spain

^gDepartamento de Cardiología, Hospital de Galdakao, Galdácano, Vizcaya, Spain

Article history:

Received 20 December 2010

Accepted 4 March 2011

Available online 2 June 2011

Keywords:

Hypertension

Control

Risk factors

Lifestyle

ABSTRACT

Introduction and objectives: Hypertension is one of the most prevalent and poorly controlled risk factors, especially in patients with established cardiovascular disease (CVD). The aim of this study was to describe the rate of blood pressure (BP) control and related risk factors.

Methods: Multicenter, cross-sectional and observational registry of patients with hypertension recruited from cardiology and primary care outpatient clinics. Controlled BP defined as <140/90 mmHg.

Results: 55.4% of the 10 743 patients included had controlled BP and these had a slightly higher mean age. Patients with uncontrolled BP were more frequently male, with a higher prevalence of active smokers, obese patients, and patients with diabetes. The rate of controlled BP was similar in patients with or without CVD. Patients with uncontrolled BP had higher levels of blood glucose, total cholesterol, low density lipoproteins and uric acid. Patients with uncontrolled BP were receiving a slightly higher mean number of antihypertensive drugs compared to patients with controlled BP. Patients with CVD were more frequently receiving a renin-angiotensin-aldosterone axis inhibitor: 83.5% vs. 73.2% ($P < .01$). Multivariate analysis identified obesity and current smoking as independently associated with uncontrolled BP, both in patients with or without CVD, as well as relevant differences between the two groups on other factors.

Conclusions: Regardless of the presence of CVD, 55% of hypertensive patients had controlled BP. Lifestyle and diet, especially smoking and obesity, are independently associated with lack of BP control.

© 2011 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.

Factores asociados a la falta de control de la hipertensión arterial en pacientes con y sin enfermedad cardiovascular

RESUMEN

Introducción y objetivos: La hipertensión arterial es uno de los factores de riesgo más prevalentes y peor controlados, especialmente en los pacientes con enfermedad cardiovascular (ECV) establecida. El objetivo del estudio es describir el control de la presión arterial (PA) y las características asociadas.

Métodos: Registro multicéntrico, transversal y observacional de pacientes con hipertensión arterial reclutados en consultas de cardiología y atención primaria. Se consideró PA controlada la < 140/90 mmHg.

Resultados: El 55,4% de los 10.743 pacientes incluidos presentaron PA controlada y estos tenían una media de edad ligeramente superior. Entre los pacientes con PA no controlada había mayor prevalencia de sexo masculino y pacientes con tabaquismo activo, obesidad y diabetes mellitus. El grado de control de la PA fue similar en los pacientes con y sin ECV. Los pacientes con PA no controlada presentaban valores más elevados de glucemia, colesterol total, LDL y ácido úrico. Los pacientes con PA no controlada estaban recibiendo una media ligeramente superior de fármacos antihipertensivos respecto a los que tenían la PA controlada. Los pacientes con ECV estaban tratados más frecuentemente con algún fármaco que bloquease el sistema renina-angiotensina-aldosterona: el 83,5 frente al 73,2% ($p < 0,01$). El análisis multivariable identificó que la obesidad y el tabaquismo activo se asociaban a la falta de control de la PA tanto en pacientes con ECV como sin ella y diferencias relevantes en los demás factores entre unos y otros.

Palabras clave:

Hipertensión arterial

Control

Factores de riesgo

Estilos de vida

* Corresponding author: Departamento de Cardiología, Hospital Universitario de San Juan, Ctra. Valencia-Alicante s/n, 03550 Sant Joan d'Alacant, Alicante, Spain.

E-mail address: acorderofort@gmail.com (A. Cordero).

Conclusiones: El 55% de los pacientes con hipertensión arterial tenían controlada la PA, independientemente de la presencia de ECV. Los estilos de vida y alimentación, especialmente el tabaquismo y la obesidad, se relacionan independientemente con la falta de control de la PA.

© 2011 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L. Todos los derechos reservados.

Abbreviations

ACEI: angiotensin-converter enzyme inhibitor
 ARA II: angiotensin II AT1 receptor antagonists
 BMI: body mass index
 BP: blood pressure
 CVD: cardiovascular disease
 DM: diabetes mellitus
 HT: hypertension
 RAAS: renin-angiotensin-aldosterone system

INTRODUCTION

Hypertension (HT) is one of the most prevalent population risk factors,^{1–3} especially in patients with established cardiovascular disease (CVD).^{4–7} Controlling HT leads to significant reductions in the prevalence and incidence of target organ damage^{8,9} and mortality from CVD.^{10,11} However, HT is also one of the most poorly controlled risk factors in patients with and without CVD.^{4,6,7,12} This highlights the difficulties involved in regulating and controlling blood pressure (BP) and the need to consider lifestyle and diet as well as tolerance and adherence to treatment with several families of antihypertensive drug.¹³

Controlling HT often requires the use of several antihypertensive agents, especially in elderly patients or those with stroke or diabetes mellitus (DM).¹⁴ The European Society of Cardiology and European Society of Hypertension (ESC/ESH) guidelines for the treatment of HT have emphasized that all drugs are equally useful in controlling the condition and that the goal of treatment should be to maximize reduction of cardiovascular risk.¹⁴ However, they also listed a number of situations in which a particular group of drugs should be used, especially when CVD is present. Through this analysis of data from the CARDIOTENS 2009 study, we aimed to investigate BP control in a large contemporary sample of patients diagnosed with HT and to determine the variables associated with control in patients with and without CVD.

METHODS

Study Design

The CARDIOTENS 2009 registry was an observational, multicenter, cross-sectional epidemiological study designed by the Hypertension Section of the Spanish Society of Cardiology, and supported by the Research Agency of the Spanish Society of Cardiology. Its aim was to determine the prevalence and control of HT in clinical practice. Patients were recruited from primary care and outpatient cardiology clinics. Inclusion criteria were age ≥ 18 years, possibility of access to the complete clinical record and previous diagnoses of CVD, and signed informed consent to participate provided by the patient or a legal representative. Exclusion criteria were addiction to or consumption of illegal drugs (cocaine, cannabis, psychotropic drugs) and refusal to provide written informed consent. Through member lists of the

Hypertension Section of the Spanish Society of Cardiology and listings of doctors in health-care areas in Spain's 41 provinces, 542 physicians were randomly selected. Of those, 89.1% were from primary care settings and 10.9% from cardiology outpatient clinics. Each participating physician agreed to include the first 6 patients meeting the study inclusion criteria on each day of the first week of November 2009. In total, 25 137 patients were recruited, of whom 15 102 (60.1%) had some risk factors or CVD. For the present study, we analyzed the 10 743 patients with a history of HT.

A paper-based, study-specific questionnaire was developed and completed for each patient. As in the 1999 CARDIOTENS registry,⁴ information was first collected on sociodemographic characteristics, presence of CVD, cardiovascular risk factors, and the patient's clinical history. If diagnosed CVD (ischemic heart disease, angina or heart attack, heart failure or stroke) or risk factors (dyslipidemia, HT, DM or tobacco consumption) were reported in the first section of the questionnaire, more detailed information was collected in a second section dealing with treatment, electrocardiogram (ECG) characteristics, echocardiography, and laboratory data. Patients were required to have ECG data and / or blood tests from the previous 6 months and the study protocol recommended requesting these tests if they were not available from that period. However, patients were not excluded from the study if these data were not available at the enrollment visit or subsequently. BP values and heart rate were collected at the time of consultation. The data collection protocol had to be corrected after printing as diuretics were not included in the section on antihypertensive treatment, but in "other treatments."

Study Variables

HT was considered to be present if 2 consecutive measurements $\geq 140/90$ mmHg were obtained or if the patient was taking antihypertensive treatment. HT was considered controlled if the objectives in the re-evaluated 2009 guidelines were met ($<140/90$ mmHg).¹⁵ A patient was considered to have a history of dyslipidemia if a prior diagnosis was recorded in the patient's medical records or if they had total cholesterol >220 mg/dl or low density lipoproteins (LDL) >160 mg/dl.¹⁶ Likewise, patients were considered to have DM if there was a prior record of the diagnosis in the medical records, if the patient was taking drug treatment for the disease, or if fasting blood glucose levels of >126 mg/dl were recorded on 2 consecutive occasions.¹⁷ Patients were considered obese if they had a body mass index (BMI) >30 and were considered to have abdominal obesity when waist circumference was >102 cm in men or >88 cm in women.¹⁶ The glomerular filtration rate was estimated from serum creatinine using the formula from the Modification of Diet in Renal Disease study¹⁸: $186 \times \text{creatinine} - 1154 \times \text{age} - 0.203 (\times 0.742 \text{ for women})$.

A history of atrial fibrillation was recorded if it was included in any medical report or if there was any ECG recording in the patient's clinical history. A history of ischemic heart disease was recorded for all patients whose medical records or medical reports provided by the patient showed a prior history of myocardial infarction, stable or unstable angina, percutaneous or surgical coronary revascularization, or positive results on ischemia induction (exercise stress test, scintigraphy, stress echocardiogram, etc.). Heart failure was

recorded for patients with at least one hospital admission in which this diagnosis was recorded at discharge, as well as for patients with signs and symptoms of the disease and a compatible imaging test (echocardiogram, chest X-ray.). A history of stroke was recorded when a diagnosis of ischemic, hemorrhagic, or transient stroke was included in medical records or a medical report. A history of claudication when walking, lower extremity revascularization, amputation, or an established diagnosis were coded as peripheral arterial disease. The analysis of CVD patients was performed after pooling results from patients with ischemic heart disease, heart failure, peripheral arterial disease, or stroke. Chronic obstructive pulmonary disease (COPD) was recorded as present if the diagnosis figured in the clinical history or if the patient was taking specific medication for the disease.

Statistical Analysis

Data were processed using SPSS 15.0 (SPSS Inc., Chicago, Illinois, United States) and 10.0/SE STATA (Stata Corp, College Station, Texas, United States). All variables showed a normal distribution and are presented as means \pm standard deviation. Categorical variables were assessed using the χ^2 test and continuous variables using the Student t test or ANOVA, depending on the number of groups to be compared. Multivariate analysis was performed using binary logistic regression with the forward conditional method. Uncontrolled blood pressure ($>140/90$ mmHg) was entered as the dependent variable and independent variables were those found to be statistically significant in univariate analysis and could have clinically plausible involvement. Independent variables included in the final model were age, sex, DM, current smoker, dyslipidemia, BMI >30 , abdominal obesity, COPD, and number of antihypertensive drugs. The possible effect of presence of CVD on the associations explored in the multivariate model was evaluated by analyzing interactions. Model calibration was assessed using the Hosmer-Lemeshow statistic. The model's discriminatory power was assessed using the area under the

ROC (receiver-operator characteristics) curve obtained by analyzing the probability of the value predicted by the multivariate model. Internal cross-validation was used to affirm the robustness of the analysis by evaluating the predictive value of the multivariable model in a random selection of 25% ($n = 2637$) of the sample. The results of the multivariate model are adjusted and presented as odds ratios and 95% confidence intervals (CI). Rate of BP control was compared between the two registries using the Student t test. Percentages in each of the records were used to calculate the variance. Statistical significance was set at $P < .05$.

RESULTS

Of the 10 743 patients with HT, 5949 (55.4%; 95% CI, 55.1%-55.7%) had controlled BP, compared with 40% (95% CI, 39.9%-40.1%) in the 1999 CARDIOTENS registry, giving a relative increase of 38.5% ($P < .01$) in the rate of BP control. Patients with uncontrolled BP were slightly younger and more frequently male, with a higher prevalence of active smokers, obese patients, and patients with DM (Table 1). Although no differences were observed in the prevalence of each individual CVD, patients with uncontrolled BP had more often had at least one of the CVDs studied. Nevertheless, the degree of BP control did not vary by presence or absence of CVD (Fig. 1). The results of laboratory tests showed that patients with uncontrolled BP had higher levels of blood glucose, total cholesterol, LDL, and uric acid (Table 2).

Patients with uncontrolled BP were receiving a slightly higher mean number of antihypertensive drugs compared to those with controlled BP: mean, 1.57 ± 0.80 vs. 1.45 ± 0.78 ($P < .01$); median, 1 (1-2) vs. 1 (1-2) ($P < .01$). In general, patients with CVD were treated more frequently (83.5% compared to 73.2% in patients without CVD; $P < .01$) with drugs that block the renin-angiotensin-aldosterone system (RAAS), such as angiotensin enzyme converting (ACE) inhibitors or angiotensin II AT1 receptor antagonists (ARA). Figure 2 shows the antihypertensive treatments recorded and

Table 1
General Characteristics of the Population in Terms of Blood Pressure Control

	Total	Controlled BP	Uncontrolled BP	P
Patients, n (%)	10 743 (100)	5949 (55.4)	4794 (44.6)	
Age	66.1 \pm 12.7	66.5 \pm 12.7	65.5 \pm 12.8	< .01
Male	50.1	48.8	51.7	< .01
Systolic BP (mmHg)	138.5 \pm 15.1	127.6 \pm 8.7	149.4 \pm 11.9	< .01
Diastolic BP (mmHg)	80 \pm 11.2	75.1 \pm 8.6	84.9 \pm 11.5	< .01
Abdominal girth (cm)	97.8 \pm 14.1	96.3 \pm 13.8	99.5 \pm 14.3	< .01
Abdominal obesity	36.1	31.5	41.8	< .01
BMI	28.9 \pm 4.8	28.5 \pm 4.7	29.3 \pm 4.9	< .01
BMI >30	30.7	25.9	36.6	< .01
Diabetes mellitus	32.6	31.4	34.1	< .01
Dyslipidemia	49.8	49.4	50.3	.37
Smoker	13.9	11.4	17.1	< .01
Prior IHD	18.6	18.2	19.1	.21
Prior heart failure	12.5	12.4	12.7	.54
Prior stroke	7	6.9	7.2	.57
LVH	17.2	14.9	20.1	< .01
Peripheral arterial disease	5.1	4.7	5.5	.04
Atrial fibrillation	12.5	12.6	12.4	.78
CVD	32.9	32.1	33.9	.04
COPD	13.4	12.5	14.6	< .01

BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease (stroke, heart failure, or peripheral arterial disease); IHD, ischemic heart disease; LVH, left ventricular hypertrophy. Quantitative variables are presented as mean \pm standard deviation.




Figure 1. Blood pressure control by presence or absence of cardiovascular disease and each type of heart disease. AF, atrial fibrillation; BP, blood pressure; CVD, cardiovascular disease.

Table 2

Results of Patient Blood Tests According to Degree of Blood Pressure Control

	Total	Controlled BP	Uncontrolled BP	P
Glycemia (mg/dl)	112.4 ± 36.1	109.8 ± 34.4	115.2 ± 37.6	< .01
Total cholesterol (mg/dl)	203 ± 43.5	198.9 ± 42.3	207.6 ± 44.4	< .01
LDL (mg/dl)	122.2 ± 36	118.8 ± 34.3	126.1 ± 37.5	< .01
HDL (mg/dl)	52.6 ± 15.7	52.9 ± 15.5	52.3 ± 15.9	.06
Triglycerides (mg/dl)	143.1 ± 67.3	138.3 ± 67.1	148.5 ± 67.2	< .01
Creatinine (mg/dl)	0.75 ± 0.81	0.76 ± 0.84	0.75 ± 0.77	.81
Glomerular filtration (ml/min/1.72 m ²)	78.2 ± 213.1	76.4 ± 61.8	80.2 ± 30.7	.49
Glycohemoglobin (%) ^a	6.8 ± 1.3	6.8 ± 1.4	6.8 ± 1.3	.22
Hemoglobin (g/dl)	13.5 ± 1.6	13.4 ± 1.5	13.5 ± 1.6	.03
Uric acid (mg/dl)	5.6 ± 1.6	5.5 ± 1.6	5.7 ± 1.6	< .01

BP, blood pressure; HDL, high density lipoproteins; LDL, low density lipoproteins. Quantitative variables are presented as mean ± standard deviation.

^a Only in patients with a history of diabetes mellitus.

indicates that there were no major differences in treatment strategies based on BP control.

Finally, we performed a multivariate analysis that included all clinically plausible variables which had shown a statistically significant difference in bivariate analysis. The analysis showed a significant interaction related to lack of BP control between presence of CVD and being male ($P < .01$), dyslipidemia ($P = .04$), the number of antihypertensive drugs ($P < .01$), and COPD ($P = .01$). As shown in Table 3, obesity and active smoking were associated with lack of BP control in patients with and without CVD. The model showed a satisfactory fit ($P = .3$, $\chi^2 = 6.94$) and good discriminative power (area under the curve = 0.73; 95% CI, 0.71 to 0.75; $P < .01$). The validation analysis showed similar values in the randomly selected 25% of the sample (AUC = 0.71; 95% CI, 0.68 to 0.76; $P < .01$).

DISCUSSION

The main result of this analysis of the CARDIOTENS 2009 data is that lack of BP control is associated with factors related to lifestyle

and diet, especially obesity and smoking, and that the presence of CVD interacts with BP control. Patients enrolled in the registry showed similar characteristics to those recruited in other studies^{2,6,12,19-23} so the present results can likely be extrapolated to daily clinical practice. The rate of controlled BP was higher than that observed in previous HT registries^{4,12} and coincides with the growing trend reported in other countries, including the United Kingdom, which reported a rate of controlled BP of 52%,²² and the United States, with a corresponding figure of 50.1%.² Comparison with the 1999 CARDIOTENS registry also showed a significant and relevant increase of 38.5% in the rate of HT control.

Measures aimed at changing dietary patterns and sedentary lifestyles are the first step in treating HT,¹⁴ though they are also useful in combating other risk factors such as hypercholesterolemia¹⁶ or DM¹⁷ and should be maintained even when initiating or maintaining drug treatment. However, the number of scientific publications dealing with lifestyle control and diet in cardiovascular prevention is much lower than those addressing risk factors, which probably reflects the lower interest in this aspect of treatment.²⁴ Obesity forms the pathophysiological basis underlying most cardiovascular risk factors²⁵ and is also an independent




Figure 2. Utilization rate of each family of antihypertensive drugs or antihypertensive strategy based on the degree of blood pressure control. ACE, angiotensin-converting enzyme; ARA, angiotensin II AT1 receptor antagonists; BB, betablockers; BP, blood pressure; CCA, calcium channel antagonist; Diur, diuretics.

risk factor for CVD.²⁶ It is highly prevalent in patients with HT, though weight loss is often an elusive goal despite its known benefits for HT and associated metabolic abnormalities.²⁷

The relationship between smoking and CVD has been clearly established, particularly in terms of its involvement in atherosclerosis. Our results show that smoking is also independently associated with lack of BP control and therefore they extend the relevance of tobacco control in cardiovascular prevention. Smoking induces endothelial dysfunction, vasoconstriction, insulin resistance, and dyslipidemia, certain forms of which could explain our results.²⁸ On the other hand, smokers are more sedentary and have

less healthy²⁹ diets and these are factors which can directly raise BP. Unfavorable lifestyles and diets are also associated with poorer compliance with medical treatment³⁰ and a different perception of individual cardiovascular risk.

DM, old age, and CVD are usually considered impediments to BP control.¹⁴ The VIIDA registry, which was also carried out in Spain, identified DM and left ventricular hypertrophy as the main factors associated with lack of BP control, while CVD was associated with greater control.³¹ In a sub-analysis of the PREV-ICTUS study, which included patients with HT aged >60 years, obesity was identified as one of the factors independently associated with lack of BP control.³² In a registry of patients with CVD recruited in primary care settings, obesity, DM, peripheral arterial disease, and prior stroke were also identified as factors associated with lack of BP control.³³ Our data also showed obesity to be a factor in poor BP control, but further identified smoking as a risk factor. Smoking is not mentioned as a risk factor in any of the earlier registries. Moreover, the fact that diabetes is not associated with poorer BP control could be explained by the fact that we adopted the goal for BP control (below 140/90 mmHg) recommended in the European Society of Hypertension's updated treatment guidelines for HT.¹⁵

We also found that age and CVD were not associated with worse BP control, which could reflect an improvement in the treatment of these patients. However, a significant interaction of CVD in the relationship between some variables and lack of BP control was observed. The above mentioned United States² and United Kingdom²² registries used a population design, but did not analyze differences in the degree of BP control based on the presence of CVD. Our results provide evidence that the presence of CVD modifies the association of certain variables to lack of BP control. Of particular relevance is the finding that DM is associated with lack of BP control only in patients with CVD. This finding coincides with those of previous registries³¹ and could explain why patients with DM have not experienced the same decline in CVD mortality as nondiabetic patients,³⁴ despite the known mortality benefits associated with better control of cardiovascular HT.¹¹ The number of antihypertensive drugs used showed a much weaker association with stroke, which reflects use of these drugs for indications other than the mere control of BP. These include the antianginal effectiveness of betablockers, calcium antagonists or ACE inhibitors and ARA in the presence of heart failure or ventricular dysfunction. Furthermore, the presence of CVD cancelled out the association between being male and lack of BP control observed in patients without CVD. On the other hand, this phenomenon was observed in the case of dyslipidemia, which was associated with better BP control in CVD patients, which probably indicates increased awareness about the disease, the need to follow lifestyle and dietary measures and to comply appropriately with the recommended medication.

Table 3
Results of Multivariate Analysis of Variables Associated With Uncontrolled Blood Pressure

Variables	All patients	Patients with CVD
Age	1 (0.99-1); $P = .2$	0.99 (0.99-1); $P = .84$
Male	1.05 (1.03-1.08); $P < .01$	0.97 (0.95-1); $P = .1$
Smoker	1.2 (1.06-1.37); $P < .01$	1.62 (1.28-2.05); $P < .01$
BMI > 30	1.35 (1.21-1.51); $P < .01$	1.36 (1.17-1.59); $P < .01$
Abdominal obesity	1.38 (1.24-1.54); $P < .01$	1.2 (1.04-1.4); $P = .01$
Diabetes mellitus	1.05 (0.94-1.18); $P = .38$	1.16 (1.01-1.34); $P = .04$
Dyslipidemia	1.01 (1.06-1.37); $P = .89$	0.83 (0.72-0.97); $P = .02$
Number of antihypertensive drugs	1.45 (1.35-1.55); $P < .01$	1.14 (1.05-1.25); $P < .01$
COPD	1.17 (0.99-1.4); $P = .07$	0.84 (0.71-0.99); $P = .01$

BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease (including ischemic heart disease, heart failure, stroke and peripheral arterial disease).

Finally, if we compare data from this study with that from its predecessor, performed in 1999,⁴ it can be observed that the level of BP control has noticeably increased, as BP was controlled in fewer than 40% of patients with HT but without CVD and in 20% of patients with CVD in the earlier study. This trend towards improved control rates is consistent with results published recently in other countries, such as 50.1% according to the third NHANES (National Health and Nutrition Examination Survey)² the United States or 54% in the United Kingdom.²² These figures coincide almost exactly with our results. Moreover, although RAAS blockade was used in under 50% of patients with CVD in the previous registry its use is now widespread, a finding which also mirrors results from other national^{12,19,20} and international^{22,23} registries. The fact that the rate of control in the current registry is similar in patients with and without CVD may be due to the unification of the control target (<140/90 mmHg¹⁵), but also to improvements in patient treatment.^{7,20} The evolution in treatment can be influenced by differences in diagnostic criteria, marketing of new drugs, or prescription-related legislation, but it certainly reflects an important advance in the treatment of patients with HT.

The CARDIOTENS 2009 registry had some limitations that deserve consideration. First, as a cross-sectional observational study, it is not possible to identify risk factors, only associations between clinical variables. Also, these designs often lead to the observation that patients with poorer BP control tend to have more treatments due to their being more complex patients. It is also important to note that other factors that could have been identified as limiting BP control, including race, cultural factors, adherence, other concomitant treatments, or duration of HT, were not analyzed. Moreover, the fact that most patients were included by primary care physicians may mean that they are not representative of other areas of medicine in which HT patients are treated, such as internal medicine, nephrology, or neurology. Another important limitation is that investigators were not selected randomly from all physicians nationwide, but by randomly inviting doctors registered in community listings. Physicians participating in the study may therefore have been more motivated and more aware of the importance of these studies. Notably, the prevalence of diuretic use was very low, a finding which is clearly related to the data collection protocol, which had to be corrected once printed.

CONCLUSIONS

Regardless of the presence of CVD, 55% of patients with HT had controlled BP. Lifestyle and diet, especially smoking and obesity, were related to lack of BP control.

FUNDING

The CARDIOTENS 2009 registry was supported by an unrestricted grant from RECORDATI laboratories, Spain.

CONFLICTS OF INTEREST

None declared.

REFERENCES

- Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association. *Circulation*. 2011;123:e18-209.
- Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. *JAMA*. 2010;303:2043-50.
- Gabriel R, Alonso M, Segura A, Tormo MJ, Artigao LM, Banegas JR, et al. Prevalencia, distribución y variabilidad geográfica de los principales factores de riesgo cardiovascular en España. Análisis agrupado de datos individuales de estudios epidemiológicos poblacionales: estudio ERICE. *Rev Esp Cardiol*. 2008;61:1030-40.
- González-Juanatey JR, Alegría E, Lozano JV, Listeri JL, García JM, González-Maqueda I. Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999. *Rev Esp Cardiol*. 2001;54:139-49.
- Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. *JAMA*. 2006;295:180-9.
- Kotseva K, Wood D, De BG, De BD, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. *Lancet*. 2009;373:929-40.
- Bertomeu V, Cordero A, Quiles J, Mazón P, Aznar J, Bueno H. Control de los factores de riesgo y tratamiento de la cardiopatía isquémica: Registro TRECE. *Rev Esp Cardiol*. 2009;62:807-11.
- Verdecchia P, Staessen JA, Angeli F, De SG, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. *Lancet*. 2009;374:525-33.
- Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. *Circulation*. 2009;120:1380-9.
- Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. *J Hypertens*. 2009;27:1360-9.
- Wijeyesundera HC, Machado M, Farahati F, Wang X, Witteman W, Van DV, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. *JAMA*. 2010;303:1841-7.
- González-Juanatey JR, Alegría-Ezquerro E, Aznar-Costa J, Bertomeu-Martínez V, Franch-Nadal J, Palma-Gamiz JL. Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales y especializadas. *Rev Esp Cardiol*. 2006;59:801-6.
- Friedman O, McAlister FA, Yun L, Campbell NR, Tu K. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. *Am J Med*. 2010;123:173-81.
- Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007;25:1105-87.
- Mancia G, Laurent S, Gabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens*. 2009;27:2121-58.
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486-97.
- Ryden L, Standl E, Bartnik M, Van den BG, Betteridge J, De Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J*. 2007;28:88-136.
- K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39:1-266.
- Cordero A, Bertomeu-Martínez V, Mazón P, Quiles J, Aznar J, Bueno H. Differences in medical treatment of chronic coronary heart disease patients according to medical specialties. *Cardiovasc Ther*. 2009;27:173-80.
- Otero-Ravina F, Grigorian-Shamagian L, Fransi-Galiana L, Nazara-Otero C, Fernández-Villaverde JM, Del Álamo-Alonso A, et al. Morbidity and mortality among heart failure patients in Galicia, N. W. Spain: the GALICAP Study. *Int J Cardiol*. 2009;136:56-63.
- Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. *JAMA*. 2010;304:1350-7.
- Falascetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. *Hypertension*. 2009;53:480-6.
- Dewilde S, Carey IM, Richards N, Whincup PH, Cook DG. Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment. *Heart*. 2008;94:83-8.
- Mozaffarian D, Wilson PW, Kannel WB. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. *Circulation*. 2008;117:3031-8.
- Cordero A, León M, Andrés E, Ordoñez B, Laclaustra M, Grima A, et al. Gender differences in obesity related cardiovascular risk factors in Spain. *Prev Med*. 2009;48:134-9.
- Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. *Lancet*. 2005;366:1640-9.

27. Cordero A, Bertomeu-Martínez V, Mazón P, Martín-Raymondi D, Palma JL, Anguita M, et al. Short-term metabolic changes achieved by weight loss in hypertensive patients. *Int J Cardiol*. 2010 Sep 17 [Epub ahead of print].
28. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *BMJ*. 1989;298:784-8.
29. Kvaavik E, Meyer HE, Tverdal A. Food habits, physical activity and body mass index in relation to smoking status in 40-42 year old Norwegian women and men. *Prev Med*. 2004;38:1-5.
30. Aggarwal B, Mosca L. Lifestyle and psychosocial risk factors predict non-adherence to medication. *Ann Behav Med*. 2010;40:228-33.
31. Bertomeu V, Fácila L, González-Juanatey JR, Cea-Calvo L, Aznar J, Mazón P, et al. Control de las cifras de presión arterial en los pacientes hipertensos con hipertrofia ventricular: estudio VIIDA. *Rev Esp Cardiol*. 2007;60:1257-63.
32. Redón J, Cea-Calvo L, Moreno B, Monereo S, Gil-Guillén V, Lozano JV, et al. Independent impact of obesity and fat distribution in hypertension prevalence and control in the elderly. *J Hypertens*. 2008;26:1757-64.
33. Orozco-Beltrán D, Brotons C, Moral I, Soriano N, Del Valle MA, Rodríguez AI, et al. Determinantes del control de la presión arterial y los lípidos en pacientes con enfermedad cardiovascular (estudio PREseAP). *Rev Esp Cardiol*. 2008;61:317-21.
34. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB, Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. *Circulation*. 2009;119:1728-35.